Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-2409 + Valacyclovir in Resectable NSCLC
NCT03131037Phase 1Completed
- Sponsor
- Candel Therapeutics
- Start
- May 2017
- Primary completion
- Dec 2021
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of aglatimagene besadenovec in non-small cell lung cancer (NSCLC), sponsored by Candel Therapeutics. Primary endpoints: Incidence of treatment emergent adverse events at 6 weeks and Immunologic changes induced by CAN-2409 plus prodrug. Started May 2017; status: completed.
02
Drugs
aglatimagene besadenovec
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03131037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03131037.